Regentis Biomaterials Ltd. (NYSE American: RGNT) has moved its lead product, GelrinC, into the pivotal stage of development, according to a recent article featured by MissionIR. GelrinC is an off-the-shelf hydrogel implant designed to support the body’s natural regeneration of damaged knee cartilage. If successful, it could address a significant unmet need: approximately 470,000 cartilage knee repair cases annually in the U.S. where no off-the-shelf treatment is currently available.
The technology is delivered as a liquid and cured in place with UV light, forming a temporary scaffold that gradually degrades over roughly six to nine months. This creates an environment intended to support the development of new cartilage without requiring cell harvesting or laboratory expansion. The company cites encouraging Phase 2 data from 56 patients, including improvements in pain and function through four years of follow-up. Imaging has shown regenerated tissue with characteristics more closely resembling native hyaline cartilage.
GelrinC has already received CE Mark approval in Europe. An FDA-authorized pivotal study is underway in the U.S. and Europe, with two-year follow-up data intended to support a potential Premarket Approval application. This pivotal stage is critical because it represents the final clinical hurdle before a possible U.S. market entry, which would open a substantial commercial opportunity.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.
The announcement was disseminated as part of a paid investor awareness and marketing engagement. The latest news and updates relating to RGNT are available in the company’s newsroom at Regentis Biomaterials (NYSE American: RGNT). To view the full article, visit https://ibn.fm/bMdpZ. For more information on MissionIR, which is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, visit www.MissionIR.com. The platform provides access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. It also offers article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
